Partnership
|
Business Development
Even in the emerging markets, today's pharmaceutical licensing environment is extremely competitive. To be successful, a leading company like NewBridge must be able to move quickly to identify, evaluate, and negotiate licenses that create value to both the partner and NewBridge, as well as serving the needs of our healthcare providers and their patients. Since the founding of the Company, NewBridge's management team has a clear and extensive record of executing successful business development, licensing and strategic alliance management. We maintain our market edge through a highly focused strategy of identifying, acquiring and maximizing the potential of approved and late-stage development therapeutics. We are a unified team and are structured for quick action and adhere to a philosophy of negotiations and transactions that are carried out with the highest regard for fairness, flexibility as well as speed. Product Identification With presence and capabilities built in Dubai, San Francisco, Jordan and Kuwait, we are dedicated to actively, but selectively, pursuing both global and regional opportunities. We leverage our extensive global network to identify licensing and acquisition opportunities that meet targeted strategic criteria of both a viable therapeutic alternative and an enabler of better physician care management. We conduct licensing and acquisition opportunity, screening and validating candidates through market research, medical relevance and segmentation analysis. Areas of Interest Our initial preference is to market products and late-stage candidates with a focus on oncology, endocrine and metabolic disorders (obesity and diabetes), gastroenterology, anti-infectives, cardiovascular and dermatology specialty franchises. We also actively search for new partners with Biotech, Research-based, Specialty, niche Generic, Biosimilar, OTC and point of care diagnostic opportunities. We are open to flexible deal structures, either in few key countries or the whole region. |
